Physician profile
Amy Thomas
NPI 1447838032
$5,181.70
in general payments reported to CMS, 2019-2025
27 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,269 · 2023: $1,268 · 2024: $1,378 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,827 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,827.29 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.61 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.25 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Teva Pharmaceuticals USA, INC. | $472.41 | 2022-2024 | Austedo Xr |
| Lilly USA, LLC | $318.66 | 2023-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.74 | 2022-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $239.83 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $215.49 | 2022-2025 | Gattex, Entyvio |
| Novo Nordisk INC | $204.59 | 2022-2025 | Wegovy |
| Janssen Biotech, INC. | $202.96 | 2024 | Stelara, Tremfya |
| Ibsa Pharma INC. | $157.22 | 2022-2024 | Licart, Tirosint |
| Paratek Pharmaceuticals, INC. | $137.45 | 2022-2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $135.13 | 2023 | |
| Janssen Scientific Affairs, LLC | $134.63 | 2024 | Tremfya, Remicade, Stelara |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Genzyme Corporation | $120.18 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $119.96 | 2023 | Accrufer |
| Corcept Therapeutics | $116.01 | 2023 | Korlym |
| Hologic Sales and Service, LLC | $88.55 | 2025 | Aptima |
| Dexcom, INC. | $79.31 | 2022 | |
| Ardelyx, INC. | $57.13 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $52.43 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $38.81 | 2022-2023 | Dupixent |
| Evoke Pharma, INC. | $32.12 | 2024-2025 | |
| Braintree Laboratories, INC. | $18.58 | 2022 | |
| Organon LLC | $17.60 | 2022 | |
| Fresenius Kabi USA, LLC | $13.54 | 2023 | Idacio |
| Pfizer INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.